Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$19.45 - $53.27
Next Earnings Date
May 01 2025
Next Earnings Date
May 01 2025
Latest price
Market Cap | $1.99B |
EV | $1.23B |
Shares Outstanding | 80.10M |
Beta | 2.23 |
Analyst Rating | BUY |
Analyst Target Price | $57.67 |
P/E 2025E | - |
P/Revenue 2025E | 33.17x |
Revenue | -13.50% |
EPS | -12.60% |
Operating Cash Flow | -14.70% |
Free Cash Flow | -16.70% |
Revenue | 20.40% |
EPS | -12.90% |
Operating Cash Flow | -13.30% |
Free Cash Flow | -10.50% |
Gross Margin 2025E | 100.00% |
Net Profit Margin 2025E | -494.72% |
ROE 2025E | -30.64% |
ROCE 2024 | -36.38% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Kymera Therapeutics, Inc.
KYMR
Sector
Healthcare
Industry
Biotechnology
CEO
Mainolfi, Nello
Employees
188
Website
www.kymeratx.comIPO Date
2020-08-21
Headquarters
200 Arsenal Yards Boulevard, Suite 230, Watertown, Massachusetts, 02472, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved